Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 6/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834826 | 0.88 | AAK1 (0.45) | S1PR3AAK1ALDH1A1MAPTGAA | |
| SCHEMBL2833200 | 0.88 | AAK1 (0.44) | S1PR3AAK1MAPTGAAHPGD | |
| SCHEMBL2833350 | 0.82 | S1PR3 (0.50) | S1PR3AAK1S1PR1ALDH1A1S1PR4 | |
| SCHEMBL2836601 | 0.80 | S1PR3 (0.51) | S1PR3AAK1S1PR1S1PR4 | |
| SCHEMBL2837542 | 0.79 | S1PR3 (0.43) | S1PR3AAK1S1PR1ALDH1A1MAPT | |
| SCHEMBL2835001 | 0.79 | S1PR3 (0.48) | S1PR3S1PR1ALDH1A1S1PR4CTSS | |
| SCHEMBL2832219 | 0.78 | S1PR3 (0.47) | S1PR3AAK1S1PR1ALDH1A1S1PR4 | |
| SCHEMBL2836642 | 0.78 | S1PR3 (0.48) | S1PR3S1PR1ALDH1A1S1PR4CTSS | |
| SCHEMBL2833750 | 0.78 | S1PR3 (0.48) | S1PR3S1PR1ALDH1A1S1PR4CTSS | |
| SCHEMBL2837077 | 0.78 | S1PR3 (0.53) | S1PR3AAK1ALDH1A1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | S1PR3 2311/4885AAK1 1304/4885S1PR1 1528/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | S1PR3 2311/4885AAK1 1304/4885S1PR1 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.